Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Late buying fuels Indian indices
Mon, 22 Apr Closing

The Indian equity markets traded firm throughout the trading session today. The indices began the day's proceedings on a cautious note but buying across index heavyweights intensified in the subsequent hours. Although trading remained largely rangebound in the morning session, buying activity gathered momentum in the later hours ensuring a positive close for the Indian indices. While the BSE-Sensex closed higher by 153 points, the NSE-Nifty closed higher by 51 points. The BSE Mid Cap and the BSE Small Cap indices also did well to notch gains of 1% each. Gains were largely seen in banking and consumer durables stocks. IT stocks, however, were at the receiving end.

As regards global markets, most Asian indices closed firm today while European indices have also opened in the green. The rupee was trading at Rs 54.13 to the dollar at the time of writing.

Pharma stocks closed mixed today. While Sun Pharma and Lupin found favour, Ranbaxy and Dr.Reddy's closed in the red. As per a leading business daily, Lupin is looking to grow its sales at around 25% globally over the next three years. What is more, growth is expected to come in from all markets the company is present in rather any particular one. In the highly competitive US market too, Lupin expects to sustain growth levels of around 25% in the current fiscal. The company is specifically looking to gain a strong foothold in the oral contraceptive (OC) space and has garnered 11 approvals. However, it must be noted that the US generic oral contraceptive market (OC), is largely dominated by a couple of players viz., Teva and Watson. Brand loyalty is an important attribute in the OC market. Thus, while this segment is margin lucrative, Lupin could face challenges in terms of gaining market share in that space. As far as India is concerned, the company is looking to log in healthy growth rate of 20% led by new drug launches, in-licensing agreements and strategic alliances.

Mining stocks closed firm today with the key gainers being Coal India, National Mineral Development Corporation (NMDC) and Hindustan Zinc. As per a leading business daily, 82 m tonnes (MT) of coal are expected to be imported this fiscal by power generation utilities. This is to meet the requirements of import-based fuel projects and to bridge the shortfall in domestic production. Out of 82 MT, 50 MT is to meet the shortfall in supply from Coal India and the balance 32 MT is for projects running on imported coal. In FY13, the imported coal figure stood at 31.5 MT. One of the main reasons for the increase in quantum of coal imports this fiscal is due to the commissioning of Tata Power's Mundra plant in Gujarat. Meanwhile, Coal India, on its part, has outlined an investment of Rs 50 bn for FY14 primarily to increase production.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary


What else is happening in the markets today? Dig in...

Equitymaster requests your view! Post a comment on "Late buying fuels Indian indices". Click here!

  

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)

Feb 16, 2021

A look at what India's top equity mutual funds bought and sold in January 2021.

I Would Recommend this Small-cap Stock Over Tesla (Profit Hunter)

Feb 16, 2021

Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.

Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Mar 1, 2021 (Close)

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS